Board of Directors
IPM’s Board of Directors (BOD) oversees the organization’s strategic planning, operations and finances.
Board members have extensive experience in public health, HIV prevention, pharmaceutical development, economic development, health care financing, and government operations in both developing and developed countries.
The current Board is composed of 13 members, representing countries in Africa, Europe and North America, who work in academia, government, and the for-profit and nonprofit sectors.
Each member serves on a volunteer basis for three-year terms. IPM’s chief executive officer serves as an ex officio nonvoting member of the Board.
Finance, Audit and Compensation Committee
IPM’s Finance, Audit and Compensation Committee provides advice to the IPM’s Board of Directors on the organization’s financial and fiscal health.
The committee helps ensure the organization’s financial stability and integrity as well as compliance with financial and accounting standards through review of budgets, internal controls and policies, audit findings and recommendations, and compensation and benefits.
Every year, IPM’s Board elects at least three non-employee members of the Board to serve a one-year term. The treasurer of the Board serves as committee chair.
Committee members bring substantial experience in business operations and financial management, and an understanding of accounting principles and processes.
Scientific Advisory Board
IPM's Scientific Advisory Board (SAB) was created in 2002 to provide ongoing, high-level scientific advice to IPM’s staff and BOD.
Our scientific agenda is based on a set of decision-making criteria first approved by the SAB in 2003. The original SAB did not meet regularly, but IPM established an Executive Committee of its SAB to convene annually, beginning in 2006.
Beginning in 2009, the SAB created two subcommittees, with ad hoc subcommittees to be formed if product development and clinical activities and timelines require more defined expert discussion.
The SAB is composed of members with expertise in drug development, HIV and ARV science, microbicide development, clinical evaluation, delivery system expertise, regulatory knowledge and other relevant areas.
IPM’s Board of Directors reviews, approves and updates, as needed, the “Terms of Reference for the SAB,” and is consulted on SAB composition and leadership.
Access Advisory Committee
IPM’s Access Advisory Committee provides strategic advice to help ensure the successful market introduction and long-term adoption of IPM’s dapivirine ring.
The committee provides guidance on market introduction plans, strategic partnerships and stakeholder engagement, involving women and adolescent girls, communities, program implementers and health experts to inform and shape their recommendations.
Committee members have diverse experience in the design, implementation, and monitoring and evaluation of HIV and sexual and reproductive health programs, services, research, advocacy and social marketing, primarily in eastern and southern Africa.
The current committee is composed of 12 members, representing countries in Africa, Europe and North America, who have worked in civil society, academia, government, andfor-profit and nonprofit sectors. Each volunteer member serves for a three-year term.
IPM is committed to conducting its work in an ethical manner. Read our policies below.